SCHEMBL1286676

SCHEMBL1286676

CC(=O)Cc1c[nH]cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6602444 0.83
SCHEMBL6447288 0.81
Imidazole Acetic Acid SCHEMBL27340954 0.81
Imidazole Acetic Acid SCHEMBL9099789 0.81 GABRR1 (0.41)
Imidazole Acetic Acid SCHEMBL637983 0.81
SCHEMBL8227646 0.80 ALDH1A1 (0.38)
SCHEMBL13437552 0.80 TDP1 (0.33)
SCHEMBL27456186 0.80 KDM4E (0.32)
SCHEMBL4434828 0.79
SCHEMBL9238935 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3490983-B1 DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2021-02-17 EP disclosed
US-9822134-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-11-21 US disclosed
US-9556210-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-01-31 US disclosed
US-9376421-B2 Compounds and methods for myotonic dystrophy therapy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-06-28 US disclosed
US-20160176903-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SABAG-RFA LTD. (IL) 2016-06-23 US disclosed
US-20160039850-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SABAG-RFA LTD. (IL) 2016-02-11 US disclosed
US-9217022-B2 GLP-1 receptor agonist compounds having stabilized regions ASTRAZENECA PHARMACEUTICALS LP (US) 2015-12-22 US disclosed
US-9156865-B2 System for delivering therapeutic agents into living cells and cells nuclei DELIVERSIR LTD (IL) 2015-10-13 US disclosed
EP-1845973-B1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LTD (GB) 2015-08-12 EP disclosed
US-9072794-B2 Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity HANMI SCIENCE CO., LTD (KR) 2015-07-07 US disclosed
US-7235627-B2 Derivatives of GLP-1 analogs NOVO NORDISK A/S (DK) 2007-06-26 US disclosed
US-7235627-B2 Derivatives of GLP-1 analogs NOVO NORDISK A/S (DK) 2007-06-26 US disclosed
CN-1934094-A Diaryl substituted heterocyclic 5-membered ring derivatives BANYU PHARMA CO LTD (JP) 2007-03-21 CN disclosed
US-7176214-B2 Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-13 US disclosed
WO-2006077424-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2006077428-A1 PHARMACEUTICAL COMPOUNDS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2006077414-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2006077419-A1 PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2006077425-A1 COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS ASTEX THERAPEUTICS LIMITED (GB) 2006-07-27 WO disclosed
WO-2005012256-A1 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS ASTEX THERAPEUTICS LIMITED (GB) 2005-02-10 WO disclosed